Name: Working Capital Turnover

Definition: Working capital turnover shows how efficiently the company uses its short-term resources — like cash, inventory, and receivables — to generate sales. Higher turnover means the company squeezes more sales from its working capital. Lower turnover may indicate inefficient inventory, slow collections, or too much short-term capital tied up unnecessarily.

Interpretation:
• In '2021', ETNB's working capital turnover was 0.00, showing how efficiently working capital is deployed. Industry average for Biotechnology: Pharmaceutical Preparations in '2021' stood at 0.40.
• In '2022', ETNB's working capital turnover was 0.00, showing how efficiently working capital is deployed. The figure remained stable compared to '2021'. Industry average for Biotechnology: Pharmaceutical Preparations in '2022' stood at 0.48. Industry average increased by 0.08 compared to previous year.
• In '2023', ETNB's working capital turnover was 0.00, showing how efficiently working capital is deployed. The figure remained stable compared to '2022'. Industry average for Biotechnology: Pharmaceutical Preparations in '2023' stood at 0.48. Industry average increased by 0.00 compared to previous year.
• In '2024', ETNB's working capital turnover was 0.00, showing how efficiently working capital is deployed. The figure remained stable compared to '2023'. Industry average for Biotechnology: Pharmaceutical Preparations in '2024' stood at 0.52. Industry average increased by 0.04 compared to previous year.
Overall, ETNB's working capital turnover has remained generally stable over the past 4 years.

Formula: Working Capital Turnover = Net Sales / Working Capital

Good Range: Ranges 5-20 depending on business.